Overview

  • Product nameHydralazine hydrochloride
  • Description
    DNA methylation inhibitor. Antihypertensive agent.
  • Biological descriptionInhibits DNA methylation by inhibition of MAPK (EC50 = 2.96 μM). Multiple, direct effects on vascular smooth muscle; hyperpolarization, inhibition of IP3-induced release of Ca2+ and formation of NO leading to cGMP-mediated vasodilation. DNMT inhibitor (IC50 = 2 µM).
  • Purity> 99%

Properties

    Applications

    Our Abpromise guarantee covers the use of ab120863 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Abreviews Notes
    Functional Studies Use at an assay dependent concentration.

    Hydralazine hydrochloride images

    • Jurkat cells were incubated at 37°C for 5 days with vehicle control (0 µM) and different concentrations of hydralazine hydrochloride (ab120863). Decreased expression of DNMT1 (ab19905) in Jurkat cells correlates with an increase in hydralazine hydrochloride concentration, as described in literature.

      Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 20 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab19905 at 1 µg/ml and ab8227 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.

    References for Hydralazine hydrochloride (ab120863)

    This product has been referenced in:
    • Yamanegi K  et al. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death. Int J Oncol 41:83-91 (2012). Read more (PubMed: 22576685) »
    • Kim HJ  et al. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol 7:39 (2012). Read more (PubMed: 22429326) »
    • Kao YH  et al. Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+ -ATPase and calcium homeostasis in cardiac myocytes. Lab Invest 91:1291-7 (2011). Read more (PubMed: 21747360) »
    • Sato N  et al. The vasodilatory effects of hydralazine, nicardipine, nitroglycerin, and fenoldopam in the human umbilical artery. Anesth Analg 96:539-44, table of contents (2003). Read more (PubMed: 12538209) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120863.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"